贝伐单抗联合紫杉醇和奈达铂治疗晚期及复发宫颈癌的疗效观察

目的探讨贝伐单抗联合紫杉醇和奈达铂治疗晚期及复发宫颈癌的临床疗效。方法选取2013年2月—2015年2月辽宁省肿瘤医院妇科收治的晚期及复发宫颈癌患者88例,按照治疗方法不同分为对照组和治疗组,每组各44例。对照组第1天给予紫杉醇注射液175 mg/m2,加入500 m L生理盐水中静脉滴注,3 h内滴完。第2天给予注射用奈达铂80 mg/m2进行静脉滴注。治疗组在给予对照组药物化疗前给予贝伐单抗注射液7.5 mg/kg,加入500 m L生理盐水中静脉滴注,首次应用贝伐单抗注射液输注时间应持续90 min,以后可缩短至60 min,其他治疗同对照组。两组均以3周为1个疗程,连续治疗3个疗程。观察两组的临床疗效和生活质量改善情况,观察两组患者不良反应发生情况。结果治疗后,对照组有效率为31.82%,临床获益率为70.45%;治疗组有效率为56.82%,临床获益率为88.64%,两组有效率、临床获益率比较差异有统计学意义(P0.05)。对照组和治疗组生存质量改善率分别为65.91%、84.09%,两组比较差异有统计学意义(P0.05)。两组不良反应发生情况比较差异无统计学意义。结论贝伐单抗联合紫杉醇和奈达铂治疗晚期及复发宫颈癌具有较好的临床疗效,可显著提高患者的生存质量,不良反应并未增加,具有一定的临床推广应用价值。

Clinical observation of bevacizumab combined with paclitaxel and nedaplatin in treatment of advanced and recurrent cervical cancer

Objective To investigate the clinical efficacy of bevacizumab combined with paclitaxel and nedaplatin in treatment of advanced and recurrent cervical cancer. Methods Patients (88 cases) with advanced and recurrent cervical cancer in Department of Gynaecology of Liaoning Cancer Hospital from February 2013 to February 2015 were enrolled in this study. According to the different treatment plan, patients were divided into treatment (44 cases) and control (44 cases) groups. The patients in the control group were iv administered with Paclitaxel Injection on the first day, 175 mg/m² added into normal saline 500 mL, and dropped down in 3 h. And they were iv administered with Nedaplatin for injection 80 mg/m². The patients in the treatment group were iv administered with Bevacizumab Injection before giving the chemotherapy drugs of control group, 7.5 mg/kg added into normal saline 500 mL, for the first time the infusion time should be continued for 90 min, later reduced to 60 min, and other treatment was the same as the control group. One course of treatment included 3 weeks, and two groups were treated for three courses. The clinical efficacy and improvement of life quality in two groups were evaluated, and the adverse reactions in two groups were observed. Results After treatment, the total effective rate of control group was 31.82%, and the clinical benefit rate was 70.45%, while the total effective rate of treatment group was 56.82%, and the clinical benefit rate was 88.64%, and there were differences between two groups (P< 0.05). The improvement rate of life quality in the control and treatment groups were 65.91% and 84.09%, respectively, and there were differences between two groups (P< 0.05). There was no difference between two groups about the situation of adverse reactions. Conclusion Bevacizumab combined with paclitaxel and nedaplatin has the good clinical effect in treatment of advanced and recurrent cervical cancer, and can significantly improve the life quality in patients, and at the same time adverse reactions do not increase, which has a certain clinical application value.